The cord blood banking market is an interesting market, as its rate of growth has slowed over the past couple years. When the market is assessed by the number of cord blood units stored, cord tissue units banked, and number of units transplanted, there are regions that are experiencing growth and regions in decline. In particular, cord blood markets are experiencing strong growth within Asia, are relatively flat within North America, and are in decline within Europe. Additionally, cord blood banks within Europe have been some of the most proactive banks to expand into other areas of stem cell storage. [Read more…]
Top 10 Quotes from the Perinatal Stem Cell Society Conference 2016
Over the past three days, dozens of world renowned speakers have presented their latest findings at the Perinatal Stem Cell Society Conference 2016, hosted by Kyle Cetrulo of Auxocell Laboratories and the Perinatal Stem Cell Society (IPLASS).
To capture the best moments from the conference, below are the top 10 quotes from the event, which was hosted at Aspen Meadows Resort in Aspen, CO, over March 2-4, 2016.
I took the image above as we were landing in Aspen. You can see our full photo album from the event on Flickr, featuring presenters, sponsors, and more.
To get live updates from the event, connect with me on Twitter (@StemCellMarket) or follow the hashtag #Perinatal. Enjoy! [Read more…]
We Analyzed a Decade of Historical Information on Cord Blood & Cord Tissue Markets (This Is What We Learned)
The cord blood banking market is complex. There are regions experiencing growth and regions experiencing decline. There are extremely successful cord blood banks, and banks that are going out of business or being acquired by the competition.
In addition, there are unique opportunities occurring within the cord blood space that are based on emerging technologies, such as ex vivo expansion of cord blood.
The cord tissue market is also complex, although for different reasons. Today, half of all cord blood banks worldwide offer this service and the number is accelerating. Interestingly, the mesenchymal stem cells (MSCs) contained in cord tissue may have growing opportunities relative to the hematopoietic stem cells (HSCs) contained in cord blood, because MSCs just surpassed HSCs in the scientific literature for the first time in history.
For this reason, BioInformant is offering industry-leading market intelligence for both cord blood and cord tissue markets for the next 14 days only.
Act by Feb 29, 2016, and you can get two reports for the price of one, a savings of $3,795.
CORD BLOOD + CORD TISSUE PACKAGE:
- Complete 2015-16 Global Cord Blood Banking Industry Report
- Mesenchymal Stem Cells – Advances & Applications
This is an exclusive offer available only to BioInformant readers, so enter the coupon code “CordBloodCordTissue” during checkout (for either product) and you will automatically receive the other report for free.
To compete within the global cord blood banking market, you need to be informed about both cord blood and cord tissue markets. This is your opportunity to get a strategic edge.
Texas Stem Cell Partners with Cesca Therapeutics to Use AutoXpress® Technology
Located in Rancho Cordova, California, Cesca Therapeutics specializes in the research, development, and commercialization of autologous cell-based therapeutics for regenerative medicine applications. With the stem cell and cord blood marketplace, the company is best known for it automated blood and bone marrow processing systems, such as the AutoXpress® Platform (AXP®), the MarrowXpress® Platform, the BioArchive® System, and others.
Already a dominant player with the cord blood banking markets, Cesca Therapeutics continues its dominance with today’s announcement that the Texas Stem Cell has entered into an agreement to use Cesca’s AutoXpress technology.
Located in Houston, Texas Stem Cell is a stem cell bank that offer the storage of newborn umbilical cord blood, cord tissue, and placenta. As a “hybrid” bank, it offers both private (fee-based) storage and public (free) donation of stem cell samples.
In news released today, the companies announced:
“Cesca Therapeutics Inc. (NASDAQ:KOOL), an autologous cell-based regenerative medicine company, today announced that Texas Stem Cell has committed to utilizing Cesca’s AutoXpress® AXP technology for its cord blood banking business. The AXP platform includes a ‘smart’ processing device and sterile disposable that automatically concentrates the stem cells from a cord blood unit in less than one hour and delivers them directly into Cesca’s patented sample bag which is optimized for cryopreservation and storage.
Cesca’s AXP technology is widely used in cord blood banks around the world and has been referenced in dozens of clinical publications. Recently, clinical focus on cord blood has expanded due to the emergence of protocols enabling the expansion of cord blood cells in vitro, for subsequent therapeutic use in treatments for many forms of blood cancers including leukemia and lymphomas.”
To learn more about the agreement, see the company press release from Cesca Therapeutics.
About BioInformant
As the first and only market research firm to specialize in the stem cell industry, BioInformant research has been cited by the Wall Street Journal, Xconomy, AABB, and Vogue Magazine. Serving Fortune 500 leaders that include GE Healthcare, Pfizer, and Goldman Sachs, BioInformant is your global leader in stem cell industry data.
Human Longevity Inc. Expands Role in Newborn Genome Sequencing with Strategic Acquisition of LifebankUSA from Celgene
In major news released today, Human Longevity, Inc. (HLI) announced that is is acquiring LifebankUSA, a cord blood, placental blood, and tissue bank owned by Celegene Cellular Therapeutics, a move that will position HLI to offer its newborn genome sequencing product in combination with stem cell banking services.
To learn more about the acquisition, read the full press release from Human Longevity, Inc. below.
Or, read our recent article exploring how this move will provide HLI with increased access to prenatal, neonatal, and maternal health markets, similar to the access that AMAG Pharmaceutical gained through its acquisition of Cord Blood Registry and PerkinElmer gained through its acquisition of ViaCord. [Read more…]
- « Previous Page
- 1
- …
- 20
- 21
- 22
- 23
- 24
- …
- 33
- Next Page »